Ceribell Receives FDA Clearance for Advanced AI EEG Detection
Sunnyvale, Calif., August 10, 2026 Ceribell, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted 510(k)...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Sunnyvale, Calif., August 10, 2026 Ceribell, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted 510(k)...
Waltham, Mass., August 10, 2026 Spyre Therapeutics, Inc. announced the launch of its SPY772 combination program and initiation of...
Bagsværd, Denmark, August 10, 2026 Novo Nordisk and Amazon Web Services (AWS) announced a strategic partnership aimed at accelerating...
Philadelphia, Pennsylvania, August 3, 2026 Signant Health announced the launch of Forecasting & Planning Assistâ„¢, a purpose-built agentic AI...
PASADENA, Calif., June 22, 2026 Arrowhead Pharmaceuticals has reached a major regulatory milestone after the European Commission (EC) granted...
LONDON, June 25, 2026 Evaluate, a Norstella company and a leading provider of pharmaceutical market intelligence, has been recognized...
Research Triangle Park, North Carolina, March 16, 2026 IQVIA Holdings Inc. announced the launch of IQVIA.ai, a next-generation unified...
New York, January 21, 2026 — Kyndryl, a global leader in mission-critical enterprise technology services, has unveiled a new...
